Natto: New Evidence: Vitamin K2-Fortified Yogurt Helps Improve Heart Health

A new study shows that consumption of yogurt fortified with MenaQ7® improves Vitamin K2 status significantly for healthy people, contributing to improved cardiovascular health.

OSLO, NORWAY and METUCHEN, NJ (November 5th 2015) – The Journal of Nutritional Science recently published a study1 that adds to the growing body of evidence showing that Vitamin K2 is a safe and effective supplement. Additionally, it shows that Vitamin K2 as MenaQ7® can be absorbed through yogurt, which makes the nutrient available to an even larger population.

“Consumers already recognize yogurt as a healthy choice. The fact that we can now enrich yogurt with a vitamin that the majority of the population is deficient is a major breakthrough. The study’s results imply that we, by adding MenaQ7 to a popular food item, can bring significant health benefits to a larger percentage of people,” says Eric Anderson, senior vice president of global sales and marketing at NattoPharma, exclusive global supplier of MenaQ7 Vitamin K2 as MK-7.

A number of studies have previously shown that supplementation with MenaQ7 Vitamin K2 improved cardiovascular health by reducing age-related arterial calcification, and improved bone health by increasing bone density and mass. . The new study, in which healthy patients received low doses of MK7 in a yogurt drink for three months, shows that the benefits of Vitamin K2 can be obtained through other delivery systems than traditional dietary supplements.

“This study not only confirms that short-term use of MenaQ7 can improve health, but also that yogurt is an effective way of providing the public with this important nutrient,” says Hogne Vik, CEO of NattoPharma. “We already have clinical documentation showing that children generally have a deficiency of Vitamin K2. The confirmation that our ingredient also works in a yogurt product is an important step forward. This means that we can make the nutrient available to more people, reach a younger audience, and create a healthier generation.”

To view the new study in The Journal of Nutritional Science, visit: http://journals.cambridge.org/action/displayAbstract?fromPage=online&aid=10006439&fileId=S2048679015000257.

Reference:

1 Knapen MHJ, Braam LAJL, Teunissen KJ, Zwijsen RML, Theuwissen E, Vermeer C. Yogurt drink fortified with menaquinone-7 improves vitamin K status in healthy population. J Nutr Sci. 2015; 4:e35 doi:10.1017/jns.2015.25.

# # #

About MenaQ7®

MenaQ7® is the best documented, commercially available vitamin K2 as MK-7 with guaranteed actives and stability, clinical substantiation, and international patents granted and pending. MenaQ7® is available in two varieties: natural vitamin K2 as MK-7 Crystals and nature-identical synthetic vitamin K2 as MK-7 PURE. For more information on the health benefits of MenaQ7, visit menaq7.com.

About NattoPharma

NattoPharma ASA, based in Norway, is the world’s leader in vitamin K2 research and development. NattoPharma is the exclusive international supplier of MenaQ7® Vitamin K2 as MK-7, and has a multi-year research and development program to substantiate and discover the health benefits of vitamin K2 for applications in the marketplace for functional food and dietary supplements. With a global presence, the company established its North American subsidiary, NattoPharma USA, Inc., in Metuchen, NJ. For more information, visit nattopharma.com.

For more information, please contact:

Hogne Vik, CEO NattoPharma
Cell phone: +47 97 53 53 26
E-mail: hogne.vik@nattopharma.com

Kate Quackenbush, Director of Communications
NattoPharma USA, Inc.
Phone: 609-643-0749
E-mail: kate.quackenbush@nattopharma.com

Tags:

About Us

NattoPharma, the world leader in Vitamin K2 Research and Development, has invested millions of dollars in in-vitro, in-vivo, and clinical studies to document the effects of MenaQ7® Vitamin K2 as MK-7. This commitment has created the only patented and clinically validated K2 on the market. After establishing the first commercial Vitamin K2 with its flagship brand, MenaQ7®, NattoPharma has consistently answered and met market needs through the development of new production technologies:• In 2012, the company introduced MenaQ7® Crystals, which represented an important breakthrough in the new generation of Vitamin K2 products, producing the purest natural MK-7 available.• In 2014, NattoPharma introduced the only all-trans nature-identical synthesized Vitamin K2, MenaQ7® PURE. Not only did the company succeed in changing the market with MenaQ7® PURE – offering a high-quality, competitively priced ingredient – but its efforts were rewarded with the NutrAward for Best Functional Ingredient at Natural Products West/engredea 2015. Vitamin K2 is essential for the body to utilize calcium to build healthy, strong bones and to inhibit calcium deposits in the arteries. Published clinical studies have demonstrated the high bioavailability and proof of efficacy for Nattopharma’s all-trans MK-7 products in healthy and diseased populations, for bone and cardiovascular health. NattoPharma continues to build its competitive advantage through focuson IPR and has patents both granted and pending related to relevant healthbenefits and market segments, creating extra value for its customers. And NattoPharma staff consists of professionals people with longstanding experience in medical and biochemical research as well as pharmaceutical and food supplement development. By understanding and controlling the chemistry, NattoPharma provides the market all-trans MK-7 products, while our sales and marketing team has extensive knowledge of international market demands with which it supports our partners.